PMID- 30421088
OWN - NLM
STAT- MEDLINE
DCOM- 20200402
LR  - 20200402
IS  - 1532-2807 (Electronic)
IS  - 1219-4956 (Linking)
VI  - 25
IP  - 4
DP  - 2019 Oct
TI  - The Effectiveness of Sorafenib over Other Targeted Agents in the Second-Line 
      Treatment of Metastatic Renal Cell Carcinoma: a Meta-Analysis.
PG  - 1497-1503
LID - 10.1007/s12253-018-0516-3 [doi]
AB  - The aim of the study was to perform a meta-analysis to compare the therapeutic 
      effects and adverse events (AEs) of sorafenib in second-line treatments of 
      metastatic renal cell carcinoma (mRCC). We searched online electronic databases: 
      Pubmed, Embase, Cochrane library updated on November 2017.Trials of the 
      effectiveness of sorafenib in second-line treatments of advanced RCC were 
      included, of which the main outcomes were objective response rate (ORR), 
      progression-free survival (PFS), overall survival (OS) and grade 3/4 AE. Other 
      TAs significantly reduced the risk of PFS compared to sorafenib with respect to 
      second-line treatment (HR = 0.74; 95% CI, 0.65-0.83; p < 0.00001). No significant 
      differences were, however, found in patients in terms of the ORR (HR = 1.82; 95% 
      CI, 0.98-3.35; p = 0.06). Frequencies of the most common toxicities were overall 
      similar and adverse events differed only in sensitivity analysis in rash with 
      exclusion of other TAs (HR = 0.16; 95% CI, 0.05-0.52; p = 0.002). Overall 
      survival was not debated between groups. In patients with mRCC, second-line 
      sorafenib is associated with similar ORR as other target agents. While, sorafenib 
      did not demonstrate a PFS advantage compared with other target agents, suggests 
      sorafenib may not benefit patients with mRCC. Tolerability due to toxicities is 
      similar compared sorafenib with other target agents. Further characterization of 
      the RCC oncogenic pathway, and the ongoing clinical trials should help optimize 
      the treatment option for second-line therapy of advanced renal cell carcinoma.
FAU - Huang, Hou-Feng
AU  - Huang HF
AD  - Department of Urology, Peking Union Medical College Hospital, Chinese Academy of 
      Medical Sciences and Peking Union Medical College, No.1 Shuaifuyuan, Dongcheng 
      District, Beijing, 100730, China.
FAU - Fan, Xin-Rong
AU  - Fan XR
AD  - Department of Urology, Peking Union Medical College Hospital, Chinese Academy of 
      Medical Sciences and Peking Union Medical College, No.1 Shuaifuyuan, Dongcheng 
      District, Beijing, 100730, China.
FAU - Ji, Zhi-Gang
AU  - Ji ZG
AD  - Department of Urology, Peking Union Medical College Hospital, Chinese Academy of 
      Medical Sciences and Peking Union Medical College, No.1 Shuaifuyuan, Dongcheng 
      District, Beijing, 100730, China. jzhgpumch@163.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20181112
PL  - Switzerland
TA  - Pathol Oncol Res
JT  - Pathology oncology research : POR
JID - 9706087
RN  - 0 (Antineoplastic Agents)
RN  - 9ZOQ3TZI87 (Sorafenib)
SB  - IM
MH  - Antineoplastic Agents/*therapeutic use
MH  - Carcinoma, Renal Cell/*drug therapy/metabolism/secondary
MH  - Humans
MH  - Kidney Neoplasms/*drug therapy/metabolism/pathology
MH  - Molecular Targeted Therapy
MH  - Prognosis
MH  - Sorafenib/*therapeutic use
OTO - NOTNLM
OT  - Meta-analysis
OT  - Metastatic renal cell carcinoma
OT  - Second-line therapy
OT  - Sorafenib
EDAT- 2018/11/14 06:00
MHDA- 2020/04/03 06:00
CRDT- 2018/11/14 06:00
PHST- 2017/12/10 00:00 [received]
PHST- 2018/10/21 00:00 [accepted]
PHST- 2018/11/14 06:00 [pubmed]
PHST- 2020/04/03 06:00 [medline]
PHST- 2018/11/14 06:00 [entrez]
AID - 10.1007/s12253-018-0516-3 [pii]
AID - 10.1007/s12253-018-0516-3 [doi]
PST - ppublish
SO  - Pathol Oncol Res. 2019 Oct;25(4):1497-1503. doi: 10.1007/s12253-018-0516-3. Epub 
      2018 Nov 12.